These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38984536)

  • 1. New Predictive Equation for the Estimation of Plasma Concentrations of Formed Colistin in Patients Treated With Colistimethate Sodium for Multidrug-Resistant Gram-Negative Bacterial Infections.
    Luque S; Sorlí L; Li J; Fernández-Sala X; Berenguer N; Colominas-González E; Benítez-Cano A; Montero MM; Subirana I; Prim N; García-Paricio R; Horcajada JP; Grau S
    Ther Drug Monit; 2024 Oct; 46(5):594-602. PubMed ID: 38984536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
    Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
    Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
    Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
    Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
    Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Kim EJ; Oh J; Lee K; Yu KS; Chung JY; Hwang JH; Nam EY; Kim HS; Kim M; Park JS; Song KH; Kim ES; Song J; Kim HB
    Ther Drug Monit; 2019 Feb; 41(1):102-106. PubMed ID: 30299430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
    Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: A systematic review and meta-analysis.
    Son JY; Kim S; Porsuk T; Shin S; Choi YJ
    J Infect Public Health; 2024 May; 17(5):843-853. PubMed ID: 38554590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
    Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of colistin in burn patients.
    Lee J; Han S; Jeon S; Hong T; Song W; Woo H; Yim DS
    Antimicrob Agents Chemother; 2013 May; 57(5):2141-6. PubMed ID: 23439640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
    Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
    J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
    Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
    Sorli L; Luque S; Li J; Rodríguez E; Campillo N; Fernandez X; Soldado J; Domingo I; Montero M; Grau S; Horcajada JP
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients.
    Wacharachaisurapol N; Phasomsap C; Sukkummee W; Phaisal W; Chanakul A; Wittayalertpanya S; Chariyavilaskul P; Puthanakit T
    Int J Antimicrob Agents; 2020 Jun; 55(6):105940. PubMed ID: 32179149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.